Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 3, 25 | -0.24 Increased by 0.00% | -0.16 Decreased by -50.00% |
| Sep 3, 25 | -0.22 Decreased by -46.67% | -0.21 Decreased by -4.76% |
| May 7, 25 | -0.15 Increased by +33.16% | -0.23 Increased by +34.78% |
| Feb 26, 25 | -0.25 Decreased by -8.70% | -0.25 |
| Nov 9, 24 | -0.24 Decreased by -4.35% | -0.16 Decreased by -50.00% |
| Aug 11, 24 | -0.15 Increased by +37.50% | -0.21 Increased by +28.57% |
| May 9, 24 | -0.22 Decreased by -24.67% | -0.23 Increased by +2.43% |
| Mar 29, 24 | -0.23 Increased by +14.81% | -0.23 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -7.59 M Decreased by -6.10% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -6.62 M Decreased by -50.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -4.54 M Increased by +13.62% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 96.29 K Increased by +1.91 K% | -4.81 M Increased by +5.45% | Decreased by -5.00 K% Increased by +95.30% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -7.15 M Decreased by -67.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.39 M Decreased by -22.84% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.26 M Decreased by -112.08% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.78 K Increased by +100.01% | -5.09 M Decreased by -33.94% | Decreased by -106.39 K% Decreased by -2.51 M% |